Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, a key pathological feature of MS. Preliminary imaging data have shown encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, which the company believes could enhance the development of MS therapies, including its investigational candidate Lucid-MS.
Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026. The imaging study's results could provide valuable insights into the drug's mechanism of action and help identify biomarkers for treatment response.
The collaboration with Massachusetts General Hospital leverages expertise in advanced imaging techniques to improve understanding of MS pathology. The [¹⁸F]3F4AP tracer targets potassium channels exposed during demyelination, allowing direct visualization of damaged myelin. This approach differs from conventional MRI, which detects inflammation or tissue damage indirectly. If successful, the imaging technique could become a critical tool for diagnosing MS, monitoring disease progression, and evaluating therapeutic efficacy.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company focuses on Lucid-MS development. Additionally, Quantum retains a 19.84% stake in Unbuzzd Wellness Inc., which markets UNBUZZD™, a product for alcohol misuse, and receives royalty payments on sales.
For more information on Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM. The full press release is available at https://ibn.fm/4IZ0y.
